

November 2024

Hikma is a global pharmaceutical company listed on the London Stock Exchange providing customers across North America, MENA and Europe with a broad range of generic, specialty and branded pharmaceutical products. In KSA, Hikma is a leading provider of high-quality medicines serving healthcare professionals and patients across the Kingdom for over 40 years.



Local expertise, global strength



3

Manufacturing plants



740+

Employees



1

R&D centre

Making healthcare accessible for all

We ensure our world-class medicines are within reach for all, improving access to healthcare in the Kingdom

Manufacturing high-quality medicines

Our three manufacturing plants produce essential medicines in key therapeutic areas:

General formulation plant

Manufactures a wide range of medicines in various dosage forms

Penicillin plant

Manufactures high-quality penicillin-based anti-infectives

Cephalosporin plant

Manufactures high-quality cephalosporin based anti-infectives

Hikma in KSA is ranked **#1** among the pharmaceutical companies based on sales¹

Hikma has a **5.8%** market share of the total Saudi pharmaceutical market¹

One of the leading exporting pharmaceutical companies in KSA

1st Saudi manufacturing facility to receive **US FDA approval**

A diversified portfolio of medicines

We offer patients lives in the Kingdom over 214 medicines covering 15 therapeutic areas to address a wide range of healthcare needs:



Anti-infectives



Oncology



Autoimmune



Diabetes



Central Nervous System



Cardiovascular



Gastrointestinal



Respiratory



Dermatology



Others

Highly-specialised commercial team of **250+** commercial representatives providing unsurpassed market access

Fully-owned distribution centre reaching different areas of the Kingdom from city hospitals to rural polyclinics to retail pharmacies

Reference:

1. Based on internal analysis by Hikma Pharmaceuticals PLC using data from the following source: IQVIA MIDAS® Quarterly value sales data for the countries listed below for the period :MAT Aug. 2024. Market definitions: Includes all therapeutic areas except for those ATC-3 classes that may encompass Nutrients, Infant Formulas, and Diagnostics elements within MIDAS Data, specifically ATCs SIT, T1G, T2X, T3A, V6C, and V6D, in each case reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved.

Company information

Vice President - KSA & GCC Territory:
Ma'moon Al Araidah

Hikma Pharmaceuticals - KSA

Riyadh Gallery - King Fahd Rd - Riyadh 12262
Saudi Arabia

Contacts

See www.hikma.com for contact forms